Eli Lilly & Co. vs. Relmada Therapeutics, Inc. Common Stock
Eli Lilly & Co. and Relmada Therapeutics, Inc. Common Stock are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| LLY | RLMD | |
|---|---|---|
| Market Cap | $1.11 trillion | $488.55 million |
| Revenue (TTM) | $79.67 billion | — |
| Net Income (TTM) | $26.71 billion | — |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | RLMD | |
|---|---|---|
| P/E Ratio | 41.77 | — |
| Price / Book | 32.81 | — |
| Price / Sales | 13.95 | — |
LLY and RLMD split the valuation factors evenly.
Profitability
| LLY | RLMD | |
|---|---|---|
| Net Margin | 33.53% | — |
| Return on Equity | 78.84% | — |
LLY and RLMD split the profitability factors evenly.
Dividend
| LLY | RLMD | |
|---|---|---|
| Dividend Yield | 0.56% | — |
| Payout Ratio | 23.23 | — |
LLY and RLMD split the dividend factors evenly.
Risk & Sentiment
| LLY | RLMD | |
|---|---|---|
| Short Interest | 1.29% | 0.00% |
RLMD leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, RLMD overview, RLMD financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.